Cellyan Biotechnology Co., Ltd

Cellyan Biotechnology Co., Ltd

NNASDAQ:HKPD
1.61
USD
-0.01
(-0.62%)
90.59MMarket Cap

Total Valuation

USD

As of March 31, 2026, Cellyan Biotechnology Co., Ltd carries a market capitalization of 90.59M, placing it among publicly traded companies globally. Its enterprise value stands at 91.63M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap90.59M
Enterprise Value91.63M

Share Statistics

As of March 31, 2026, Cellyan Biotechnology Co., Ltd has 7.97M shares outstanding.

Shares Outstanding7.97M

Valuation Ratios

These figures are as of March 31, 2026.

PB Ratio9.45
P/TBV Ratio9.53

Financial Position

As of March 31, 2026, Cellyan Biotechnology Co., Ltd maintains a current ratio of 3.86, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities.

Current Ratio3.86
Quick Ratio1.71
Debt / Equity13.13

Financial Efficiency

These figures cover the twelve months ended March 31, 2026.

Employee Count11.00

Stock Price Statistics

USD

As of the close on November 16, 2026, Cellyan Biotechnology Co., Ltd's stock has declined approximately 93.18% over the past 52 weeks. The 50-day moving average sits at 2.11, while the 200-day moving average is 8.54.

52-Week Price Change-93.18%
50-Day Moving Average2.11
200-Day Moving Average8.54

Balance Sheet

USD

As of March 31, 2026, Cellyan Biotechnology Co., Ltd holds 221,841.00 in cash and equivalents against 1.26M in total debt, resulting in a net debt position of 656,063.00. Total book value stands at 9.58M, with working capital of 9.14M providing operational flexibility.

Cash & Cash Equivalents221,841.00
Total Debt1.26M
Net Debt656,063.00
Equity (Book Value)9.58M
Book Value Per Share1.20
Working Capital9.14M

Stock Splits

Cellyan Biotechnology Co., Ltd's most recent stock split took place on October 26, 2026 with a 20:1 split ratio.

Last Split Date10/26/2026
Split Ratio20:1